Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Int J Cancer. 2012 Nov 15;131(10):2320-31. doi: 10.1002/ijc.27506. Epub 2012 Mar 28.
Tumor-associated macrophages (TAMs) represent a distinct malignancy-promoting phenotype suggested to play a key role in tumor formation and metastasis. We aimed to investigate the expression of the monocyte/macrophage-restricted receptor CD163 in bladder tumor biopsies and assess the potential mechanism inducing the CD163 expression in tumor cells. A high CD163 mRNA expression (n = 87) was significantly associated with a poor 13-year overall survival (log-rank test, χ(2) = 8.931; p = 0.0028). Moreover, CD163 mRNA expression was significantly increased in muscle invasive (T2-T4), p = 0.017, and aggressive (grade III/IV) cancers (p = 0.015). The expression strongly correlated with local expression of IL-6 (r = 0.72; p <0.0001) and IL-10 (r = 0.75; p <0.0001), mediators known to induce CD163 expression in vitro. CD163 immunostaining (n = 46) confirmed the association between dense TAM infiltration and histologically advanced disease. In 39% of the biopsies, CD163 immunoreactivity was also observed in tumor cells, and CD163-expressing metastatic cells were identified in lymph node biopsies (n = 8). Bladder cancer cell lines did not express CD163; however, when cocultured with macrophages the bladder cancer cell expression of CD163 was significantly induced in an IL-6/IL-10 independent manner. In conclusion, we show a strong association between CD163 mRNA expression in bladder cancer biopsies and poor patient outcome. CD163 expression was not confined to the infiltrating TAMs, but was also expressed by a significant portion of the malignant cells in both tumors and lymph nodes. CD163 expressing tumor cells may constitute a subpopulation of tumor cells with a phenotypic shift associated with epithelial-to-mesenchymal transition (EMT) and increased metastatic activity induced by TAMs.
肿瘤相关巨噬细胞(TAMs)代表一种独特的促进恶性肿瘤的表型,被认为在肿瘤的形成和转移中发挥关键作用。我们旨在研究单核细胞/巨噬细胞特异性受体 CD163 在膀胱癌活检组织中的表达,并评估诱导肿瘤细胞 CD163 表达的潜在机制。高 CD163 mRNA 表达(n = 87)与 13 年总生存率显著相关(对数秩检验,χ(2) = 8.931;p = 0.0028)。此外,CD163 mRNA 表达在肌肉浸润(T2-T4)(p = 0.017)和侵袭性(III/IV 级)癌症中显著增加(p = 0.015)。这种表达与局部白细胞介素-6(IL-6)(r = 0.72;p <0.0001)和白细胞介素-10(IL-10)(r = 0.75;p <0.0001)的表达强烈相关,这些介质已知可在体外诱导 CD163 的表达。CD163 免疫组化(n = 46)证实了密集的 TAM 浸润与组织学上的晚期疾病之间的关联。在 39%的活检中,肿瘤细胞中也观察到 CD163 免疫反应性,并且在淋巴结活检中(n = 8)也鉴定出 CD163 表达的转移性细胞。膀胱癌细胞系不表达 CD163;然而,当与巨噬细胞共培养时,膀胱癌细胞的 CD163 表达以 IL-6/IL-10 非依赖性方式显著诱导。总之,我们发现膀胱癌活检组织中 CD163 mRNA 的表达与患者预后不良之间存在很强的相关性。CD163 表达不仅局限于浸润的 TAMs,而且在肿瘤和淋巴结中的恶性细胞中也有显著表达。表达 CD163 的肿瘤细胞可能构成肿瘤细胞亚群,其表型转变与上皮-间充质转化(EMT)相关,并与 TAMs 诱导的转移活性增加有关。